This is a match-making section for OHAMR Call for proposals 2026.
H - Human Health
A - Animal HealthScale-up; bioproduction; preclinical; manufacture; commercialisation
CPI provides end-to-end bioprocess development for antimicrobial-related biologics, including upstream process optimisation (microbial and mammalian cell culture), downstream purification, and analytical development to produce material for pre-clinical and toxicology studies. Our expertise spans monoclonal antibodies, bacteriophages, recombinant proteins, and microbiome-based products to name a few, supported by formulation, stability testing, and GMP-compliant scale-up. CPI also offers cell-free protein synthesis, continuous processing, and bespoke solutions for challenging biotherapeutics, enabling seamless transition from discovery to commercialisation. CPI bridges the gap from discovery to clinical production with aspirations to bring phase 1 clinical production online in the future.
CPI could be a translational partner in developing and scaling up the process for therapeutic production. This covers preclinical production with the goal of developing phase 1 capability in the near future. With end to end capabilities in cell line development through to developing GMP compliant process, CPI can support the scale up of novel modalities in the context of AMR.
Submitted on 2025-11-26 17:47:39
« Return to the partner search tool